Exenatide vs Survodutide
Research Verdict
Neither compound has a universal evidence advantage. Both peptides serve distinct research goals with comparable evidence; choose by target mechanism.
Quick Answers
Which is better, Exenatide or Survodutide?
Neither compound has a universal evidence advantage. Both peptides serve distinct research goals with comparable evidence; choose by target mechanism.
What is the key difference between Exenatide and Survodutide?
Survodutide is a dual GLP-1/glucagon receptor agonist - the glucagon component adds hepatic fat reduction and thermogenesis beyond GLP-1 alone; exenatide is a pure GLP-1RA without glucagon activity.
Evidence Comparison
Exenatide: FDA approved since 2005 with EXSCEL cardiovascular-outcomes data and a well-characterized safety profile. Survodutide: published Phase 3 SYNCHRONIZE-1 obesity data and promising MASH evidence, but no approval. Exenatide has the mature regulatory record; survodutide has much greater weight-loss efficacy.
Evidence Context Favoring Exenatide
Research requiring an approved GLP-1RA with established long-term safety and CVOT data.
Evidence Context Favoring Survodutide
Investigational research into dual GLP-1/glucagon agonism, MASH, or next-generation obesity mechanisms.
Side-by-Side Snapshot
| Evidence grade | Exenatide: Level A Survodutide: Level B |
|---|---|
| Research status | Exenatide: FDA Approved Survodutide: Phase 3 |
| Primary category | Exenatide: Weight Loss & Metabolic Survodutide: Weight Loss & Metabolic |
| Cited studies | Exenatide: 3 Survodutide: 4 |